share_log

Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $37 Price Target

Benzinga ·  May 9 12:17

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $37 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment